Alvotech has invested over $1 billion in infrastructure dedicated to biosimilars R&D and manufacturing. Biosimilars increase patient access to vital biologic medicines. Biologics represent nearly one-half of spending in the pharmaceuticals space, in terms of healthcare cost and product development.
Alvotech targets 90 markets through a network of global partnerships, has launched two products and is currently developing a pipeline of nine additional biosimilar candidates. With over 1,000 employees all over the world, from over 60 different nationalities, we are Iceland's most diverse workplace, headquartered in a 26.000 sqm R&D and manufacturing facility on the University of Iceland's campus in downtown Reykjavik.
At this event we'll share stories about how we got here - and where we are headed.
Our speakers are:
Lilja Kjalarsdóttir, Head of Strategic Projects, Technical Operations
Sesselja Ómarsdóttir, Chief of Staff
Tanya Zharov, General Counsel & Head of Legal